Skip to content

A real-world study of aprepitant injection combined with aprepitant capsule for the prevention of nausea and vomiting induced by high-risk chemotherapy

A real-world study of aprepitant injection combined with aprepitant capsule for the prevention of nausea and vomiting induced by high-risk chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082737
Enrollment
Unknown
Registered
2024-04-07
Start date
2024-04-08
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting caused by hyperemetic chemotherapy regimens

Interventions

Case series:None

Sponsors

The First Affiliated Hospital of University of Science and Technology of China (Anhui Cancer Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female =18 years of age; 2. Patients with solid tumors requiring chemotherapy; 3. Plan a multi-day chemotherapy regimen with high emetic risk drugs; 4. Volunteer to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic constitution or allergic to aprepitant or drug excipients; 2. Patients with difficulty in taking oral drugs; 3. Pregnant or lactating women; The subject (or her partner) plans a pregnancy within 3 months of the end of the study; 4. Suffering from a serious mental illness or mental disorder, unable to understand, read and complete the diary card filling; 5. Patients who have participated in other drug clinical trials within the last three months; 6. The investigator believes that the patient has other conditions that are not suitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Complete response rate during the total observation period;

Secondary

MeasureTime frame
Complete response rate in acute phase;Complete control rate during the total observation period, acute phase, and delayed phase;Nausea relief rates during the total observation period, acute phase, and delayed phase;The proportion of subjects who did not use rescue therapy;The incidence of adverse events and adverse reactions;

Countries

China

Contacts

Public ContactYueyin Pan

The First Affiliated Hospital of University of Science and Technology of China (Anhui Cancer Hospital)

2275245132@qq.com+86 138 0569 5536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026